This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Imai, J. K.
Right arrow Articles by Stevens, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Imai, J. K.
Right arrow Articles by Stevens, D. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2004, p. 4063-4066, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.4063-4066.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Efficacy of Posaconazole in a Murine Model of Central Nervous System Aspergillosis

Jackie K. Imai,1 Gaurav Singh,1 Karl V. Clemons,1,2,3* and David A. Stevens1,2,3

California Institute for Medical Research,1 Department of Medicine, Division of Infectious Diseases, Santa Clara Valley Medical Center, San Jose,2 Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California3

Received 15 March 2004/ Returned for modification 13 May 2004/ Accepted 1 July 2004

Human central nervous system (CNS) aspergillosis has >90% mortality. We compared posaconazole with other antifungals for efficacy against murine CNS aspergillosis. All tested regimens of posaconazole were equivalent to those of amphotericin B and superior in prolonging survival and reducing CFU to those of itraconazole and caspofungin and to vehicle controls. No antifungal regimen effected cure. No toxicity was noted. Overall, posaconazole shows potential for treating CNS aspergillosis.

* Corresponding author. Mailing address: Division of Infectious Diseases, Santa Clara Valley Medical Center, 751 South Bascom Ave., San Jose, CA 95128-2699. Phone: (408) 998-4557. Fax: (408) 998-2723. E-mail: clemons{at}cimr.org.

Antimicrobial Agents and Chemotherapy, October 2004, p. 4063-4066, Vol. 48, No. 10
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.10.4063-4066.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Morris, M. I. (2009). Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 66: 225-236 [Abstract] [Full Text]  
  • Rodriguez, M. M., Pastor, F. J., Serena, C., Guarro, J. (2009). Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus. J Antimicrob Chemother 63: 361-364 [Abstract] [Full Text]  
  • Hachem, R. Y., Langston, A. A., Graybill, J. R., Perfect, J. R., Pedicone, L. D., Patino, H., Raad, I. I. (2008). Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. J Antimicrob Chemother 62: 1386-1391 [Abstract] [Full Text]  
  • Garcia-Effron, G., Dilger, A., Alcazar-Fuoli, L., Park, S., Mellado, E., Perlin, D. S. (2008). Rapid Detection of Triazole Antifungal Resistance in Aspergillus fumigatus. J. Clin. Microbiol. 46: 1200-1206 [Abstract] [Full Text]  
  • Stevens, D. A., Rendon, A., Gaona-Flores, V., Catanzaro, A., Anstead, G. M., Pedicone, L., Graybill, J. R. (2007). Posaconazole Therapy for Chronic Refractory Coccidioidomycosis. Chest 132: 952-958 [Abstract] [Full Text]  
  • Clemons, K. V., Parmar, R., Martinez, M., Stevens, D. A. (2006). Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother 58: 466-469 [Abstract] [Full Text]  
  • Clemons, K. V., Espiritu, M., Parmar, R., Stevens, D. A. (2006). Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.. Antimicrob. Agents Chemother. 50: 1293-1297 [Abstract] [Full Text]  
  • Clemons, K. V., Espiritu, M., Parmar, R., Stevens, D. A. (2005). Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis. Antimicrob. Agents Chemother. 49: 4867-4875 [Abstract] [Full Text]  
  • Imai, J., Singh, G., Fernandez, B., Clemons, K. V., Stevens, D. A. (2005). Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J Antimicrob Chemother 56: 166-171 [Abstract] [Full Text]  
  • Singh, G., Imai, J., Clemons, K. V., Stevens, D. A. (2005). Efficacy of Caspofungin against Central Nervous System Aspergillus fumigatus Infection in Mice Determined by TaqMan PCR and CFU Methods. Antimicrob. Agents Chemother. 49: 1369-1376 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»